The Efficacy and Safety of Winona Barrier Special Cream in Post-acne Erythema a Parallel Randomized Controlled Study

The goal of this study is to evaluate the efficacy and safety of winona barrier special cream in post-acne erythema(PAE). The main questions it aims to answer are: whether winona barrier special cream can improve facial skin erythema, transepidermal water loss, water content of stratum corneum, pH,melanin, lipidomic and microbiodemic in patients with PAE . type of study:clinical trial participant population/health conditions The study proposes to recruit 60 PAE patients and 20 healthy individuals The checks of patients were randomly selected to use winona barrier special cream on one side and the Basal Water on the other side. the sampes of surface skin are collected on week0, week4 and week8. Measurements of erythema, transepidermal water loss, stratum corneum water content, pH, and melanin were taken from fixed lesion sites on both cheeks before on week0, week4 and week8. Researchers will compare differences in facial lipidomics and microbiomics between patients' lesion sites and the healthy population, as well as before and after the use of creams by patients to see whether the lipidomics and microbiomics at skin lesions are different in PAE patients compared to the healthy population and whether the intensive care cream has an improved effect on them.

Inclusion Criteria: 1. adults between 18 and 40 years old, regardless of gender; 2. comply the clinical diagnostic criteria for post-acne erythema; 3. patients understand and are willing to participate in this clinical trial and voluntarily sign an informed consent form; Exclusion Criteria: 1. patients with facial comorbidities such as atopic dermatitis, rosacea, seborrheic dermatitis, and other facial skin diseases that may affect the evaluation of efficacy; 2. those who have been treated with topical acne or other skin disease medications on the face within 1 month; 3. those who have taken oral antibiotics, isotretinoin and other acne systemic treatment drugs within one month; 4. Those who have laser, intense pulse light, radio frequency, high-energy focused ultrasound and other photoelectric treatments within one month; 5. Those who are using immunosuppressants, antihistamines and antibiotics or efficacious skin care products in the week before enrollment; 6. Those who have a history of allergy to the skin care products and ingredients used this time; 7. Those with serious heart, brain, lung, liver and kidney function damage; 8. Pregnant and lactating women; 9. Those who have a history of psychological and mental illness, recent history of alcoholism or drug abuse; 10. patients who are unwilling to sign the informed consent and who are unwilling to cooperate.